Literature DB >> 31000497

Correlations Between Imaging Biomarkers and Proliferation Index Ki-67 in Lymphomas: A Systematic Review and Meta-Analysis.

Hans-Jonas Meyer1, Andreas Wienke2, Alexey Surov3.   

Abstract

BACKGROUND: Few studies investigated relationships between positron emission tomography (PET) as well as diffusion-weighted imaging (DWI) with proliferating index Ki-67 in lymphomas. The aim of the present analysis was to review the published results and perform a meta-analysis to provide data on the associations between standardized uptake values (SUV) derived from PET as well as apparent diffusion coefficient (ADC) derived from DWI with Ki-67 index in lymphomas.
MATERIALS AND METHODS: The MEDLINE library was screened for relationships between PET and DWI with Ki-67 in lymphoma up to October 2018. Overall, 22 studies with 788 patients were identified. The following data were extracted from the literature: authors, year of publication, number of patients, and correlation coefficients. Associations between SUV and Ki-67 were analyzed using Spearman correlation coefficient.
RESULTS: Fifteen studies comprising 574 patients were suitable for the analysis between maximum SUV (SUVmax) derived from fluorodeoxyglucose (FDG) PET and Ki-67. The pooled correlation coefficient was r = 0.49 (95% confidence interval [CI], 0.36-0.61). Four studies were included in the analysis between SUVmax derived from fluorothymidine (FLT) PET and Ki-67 index involving 84 patients. The pooled correlation coefficient was r = 0.46 (95% CI, 0.19-0.73). Four studies comprising 130 patients were suitable for the analysis between ADC values derived from DWI and Ki-67. The pooled correlation coefficient was r = -0.25 (95% CI, -0.53 to 0.04).
CONCLUSION: SUVmax derived from FDG and FLT PET correlated moderately and approximately equally with Ki-67 index. On the contrary, ADC values only correlated weakly inversely and might not reliably predict Ki-67 index in lymphomas.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ADC; FDT PET; FLT PET; Lymphoma; Meta analysis

Year:  2019        PMID: 31000497     DOI: 10.1016/j.clml.2019.03.005

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  3 in total

1.  The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study.

Authors:  Domenico Albano; Riccardo Laudicella; Paola Ferro; Michela Allocca; Elisabetta Abenavoli; Ambra Buschiazzo; Alessia Castellino; Agostino Chiaravalloti; Annarosa Cuccaro; Lea Cuppari; Rexhep Durmo; Laura Evangelista; Viviana Frantellizzi; Sofya Kovalchuk; Flavia Linguanti; Giulia Santo; Matteo Bauckneht; Salvatore Annunziata
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

2.  Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.

Authors:  Yoji Yamagishi; Tomomi Koiwai; Tamio Yamasaki; Takahiro Einama; Makiko Fukumura; Miyuki Hiratsuka; Takako Kono; Katsumi Hayashi; Jiro Ishida; Hideki Ueno; Hitoshi Tsuda
Journal:  BMC Cancer       Date:  2019-11-27       Impact factor: 4.430

3.  Predictive value of 3'-deoxy-3'-18F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer.

Authors:  Masayuki Sato; Yukihiro Umeda; Tetsuya Tsujikawa; Tetsuya Mori; Miwa Morikawa; Masaki Anzai; Yuko Waseda; Maiko Kadowaki; Yasushi Kiyono; Hidehiko Okazawa; Tamotsu Ishizuka
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.